Daniel Skovronsky Eli Lilly & CO (LLY) insider trading activity

Daniel Skovronsky is EVP, CSO & Pres. LRL & LLY Imm of ELI LILLY & Co. Currently has a direct ownership of 117,888 shares of LLY, which is worth approximately $97 Million. The most recent transaction as insider was on Feb 10, 2025, when has been sold 5,000 shares (Common Stock) at a price of $864.14 per share, resulting in proceeds of $4,320,700. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 118K

0.01% 3M change

4.73% 12M change

Total Value Held $97 Million

Daniel Skovronsky Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 10 2025	SELL Open market or private sale	$4,320,700 $864.14 p/Share	5,000 Reduced 4.07%	117,888 Common Stock
Feb 10 2025	BUY Grant, award, or other acquisition	$16,309,746 $868.88 p/Share	18,771 Added 12.08%	136,660 Common Stock
Feb 01 2025	SELL Payment of exercise price or tax liability	$3,246,753 $811.08 p/Share	4,003 Reduced 3.15%	122,888 Common Stock
Feb 01 2025	BUY Exercise of conversion of derivative security	-	8,989 Added 6.62%	126,892 Common Stock
Sep 11 2024	SELL Bona fide gift	-	5,724 Reduced 4.63%	117,903 Common Stock
Sep 10 2024	SELL Bona fide gift	-	111 Reduced 0.09%	123,627 Common Stock
Feb 12 2024	BUY Grant, award, or other acquisition	$9,518,026 $737.26 p/Share	12,910 Added 9.45%	123,738 Common Stock
Feb 01 2024	SELL Payment of exercise price or tax liability	$2,862,634 $645.61 p/Share	4,434 Reduced 3.85%	110,828 Common Stock
Feb 01 2024	BUY Exercise of conversion of derivative security	-	9,941 Added 7.94%	115,262 Common Stock
Nov 10 2023	SELL Bona fide gift	-	17 Reduced 0.02%	105,321 Common Stock
Aug 10 2023	SELL Bona fide gift	-	249 Reduced 0.24%	105,338 Common Stock
Feb 10 2023	BUY Grant, award, or other acquisition	$6,346,066 $345.12 p/Share	18,388 Added 14.83%	105,587 Common Stock
Feb 01 2023	SELL Payment of exercise price or tax liability	$2,421,095 $344.15 p/Share	7,035 Reduced 7.47%	87,199 Common Stock
Feb 01 2023	BUY Exercise of conversion of derivative security	-	15,675 Added 14.26%	94,234 Common Stock
Feb 09 2022	BUY Grant, award, or other acquisition	$5,493,280 $243.27 p/Share	22,581 Added 22.33%	78,559 Common Stock
Feb 01 2022	SELL Payment of exercise price or tax liability	$2,070,355 $245.39 p/Share	8,437 Reduced 13.1%	55,978 Common Stock
Feb 01 2022	BUY Exercise of conversion of derivative security	-	18,735 Added 22.53%	64,415 Common Stock
Feb 08 2021	BUY Grant, award, or other acquisition	$3,811,066 $205.77 p/Share	18,521 Added 13.8%	115,680 Common Stock
Feb 11 2020	BUY Grant, award, or other acquisition	$3,078,439 $144.25 p/Share	21,341 Added 18.01%	97,159 Common Stock
Oct 25 2019	BUY Open market or private purchase	$543,050 $108.61 p/Share	5,000 Added 6.19%	75,818 Common Stock
Feb 04 2019	BUY Grant, award, or other acquisition	$1,876,935 $120.17 p/Share	15,619 Added 18.07%	70,818 Common Stock
Jun 14 2018	BUY Open market or private purchase	$862,200 $86.22 p/Share	10,000 Added 15.34%	55,199 Common Stock

Also insider at

MYGN

MYRIAD GENETICS INC Healthcare

Director